Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) Astrazeneca Plc

22 May 2014 10:41

RNS Number : 8133H
Morgan Stanley & Co. Int'l plc
22 May 2014
 

 

 FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Morgan Stanley & Co. International plc

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

ASTRAZENECA PLC

(c) Name of the party to the offer with which exempt principal trader is connected:

 

ASTRAZENECA PLC

(d) Date dealing undertaken:

21 MAY 2014

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

 Class of relevant security

 Purchases/sales

 Total number of securities

 Highest price per unit paid/received

 Lowest price per unit paid/received

 USD 0.25 ORDINARY

 PURCHASES

 6,106

 495.6000 SEK

 484.0000 SEK

 USD 0.25 ORDINARY

 SALES

 9,233

 495.2000 SEK

 485.0000 SEK

 ADRS

 PURCHASES

 54,412.00 (Traded in ADR form)

 74.8220 USD

 73.6167 USD

 ADRS

 SALES

 54,412.00 (Traded in ADR form)

 74.8220 USD

 73.6167 USD

 

 

(b) Derivatives transactions (other than options)

 

 Class of relevant security

 Product description

e.g. CFD

 Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

 Number of reference securities

 Price per unit

 N/A

 N/A

 N/A

 N/A

 N/A

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

 Class of relevant security

 Product description e.g. call option

 Writing, purchasing, selling, varying etc.

 Number of securities to which option relates

 Exercise price per unit

 Type e.g. American, European etc.

 Expiry date

 Option money paid/ received per unit

 USD 0.25 ORDINARY

 CALL

 SALE

 284,590

 4,150.0970

 E

 12/06/2014

 0.0071 GBP

 

(ii) Exercising

 

 Class of relevant security

 Product description e.g. call option

 Number of securities

 Exercise price per unit

 N/A

 N/A

 N/A

 N/A

 

(d) Other dealings (including subscribing for new securities)

 

 Class of relevant security

 Nature of dealing e.g. subscription, conversion

 Details

 Price per unit (if applicable)

 N/A

 N/A

 N/A

 N/A

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

Date of disclosure:

22 MAY 2014

Contact name:

Darren Wickert

Telephone number:

+44 (0)20 7425 6578

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERSEUSUEFLSEDI
Date   Source Headline
6th Mar 20177:00 amRNSDirectorate Change
3rd Mar 20177:00 amRNSALLIANCE WITH SANOFI PASTEUR FOR MEDI8897
1st Mar 20174:30 pmRNSTotal Voting Rights
28th Feb 20177:02 amRNSFDA approves once-daily Qtern for type-2 diabetes
24th Feb 201712:32 pmRNSCHMP positive opinion for ZS-9 in hyperkalaemia
20th Feb 20177:00 amRNSAZ licenses Zoladex to TerSera for the US & Canada
17th Feb 20177:00 amRNSLynparza positive in metastatic BRCA breast cancer
16th Feb 201712:01 pmRNSSILIQ (BRODALUMAB) APPROVED BY US FDA
2nd Feb 20177:00 amRNSAZN: FY16 and Q4 2016 Results
1st Feb 20174:00 pmRNSTotal Voting Rights
26th Jan 201710:00 amRNSSYMBICORT GRANTED PAEDIATRIC EXCLUSIVITY IN THE US
17th Jan 20177:00 amRNSAZ 1st-line lung cancer immuno-oncology programme
3rd Jan 20174:00 pmRNSTotal Voting Rights
23rd Dec 20167:00 amRNSAZ COMPLETES SALE OF ANTIBIOTICS BUSINESS
16th Dec 20161:00 pmRNSDirector/PDMR Shareholding
9th Dec 20163:05 pmRNSFDA accepts durvalumab for BLA in bladder cancer
6th Dec 20169:30 amRNSTagrisso data shows superiority over chemotherapy
5th Dec 20167:00 amRNSAZ completes agreement for Rhinocort Aqua rights
1st Dec 20164:00 pmRNSBlock listing Interim Review
1st Dec 20163:00 pmRNSTotal Voting Rights
22nd Nov 20167:00 amRNSAZ head and neck cancer trials resume enrolment
17th Nov 20167:00 amRNSAZ out-licensing deal with Allergan completed
10th Nov 20167:04 amRNSYear-To-Date and Q3 2016 Results
9th Nov 20167:00 amRNSDirectorate Change
1st Nov 20163:30 pmRNSDealing by Person Closely Associated
1st Nov 20163:00 pmRNSTotal Voting Rights
31st Oct 20161:47 pmRNSAZ completes US Aralez agreement for Toprol-XL
27th Oct 20164:51 pmRNSAstraZeneca Head and Neck Cancer Trials
26th Oct 20167:00 amRNSPositive results in AstraZeneca Lynparza trial
18th Oct 20167:00 amRNSFDA accepts for review ZS-9 NDA for hyperkalaemia
7th Oct 20167:00 amRNSAZ DIVESTS RIGHTS TO RHINOCORT AQUA OUTSIDE US
4th Oct 20167:05 amRNSAZ agreement with Aralez for Toprol-XL in US
4th Oct 20167:00 amRNSAstraZeneca reports top-line EUCLID results in PAD
3rd Oct 20163:00 pmRNSTotal Voting Rights
3rd Oct 20167:00 amRNSMedImmune out-licenses medicine to Allergan
28th Sep 20167:00 amRNSCHANGE TO ASTRAZENECA BOARD OF DIRECTORS
26th Sep 20164:00 pmRNSDirector/PDMR Shareholding
22nd Sep 201611:00 amRNSDirector Declaration
1st Sep 20162:30 pmRNSTotal Voting Rights
1st Sep 20167:00 amRNSAstraZeneca Completes Aspen Agreement
24th Aug 20167:00 amRNSAZ TO SELL ANTIBIOTICS BUSINESS TO PFIZER
18th Aug 20161:00 pmRNSDirector Declaration
16th Aug 20167:00 amRNSAstraZeneca completes agreement with LEO Pharma
10th Aug 20162:41 pmRNSASTRAZENECA ANNOUNCES INVESTMENT IN MODERNA
9th Aug 20167:00 amRNSASTRAZENECA UPDATE ON SELUMETINIB PHASE III TRIAL
1st Aug 20162:30 pmRNSTotal Voting Rights
1st Aug 201611:00 amRNSDirector/PDMR Shareholding
28th Jul 20167:00 amRNSAZN: H1 2016 Results
27th Jul 20169:00 amRNSNotice of Results
19th Jul 20162:15 pmRNSQTERN (saxa/dapa) EU approved for type-2 diabetes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.